Lilly buddies up with Elektrofi on subcutaneous delivery of biologics

2023-10-24

交易

引进/卖出

Eli Lilly entered into a research collaboration and license agreement with Elektrofi focused on developing next-generation medicines that can be delivered subcutaneously, the latter announced Tuesday. Elektrofi’s technology is designed to allow the at-home subcutaneous self-administration of biologic therapies.

Under the deal, Eli Lilly will make an upfront payment of $20 million for exclusive rights to three targets. Elektrofi is eligible to receive over $150 million in milestones for each target, as well as tiered sales royalties up to a mid-single digit.

Eli Lilly will be responsible for clinical development and commercialisation of each product, while it has the option to expand the agreement to up to two additional targets for additional payments. Elektrofi CEO Chase Coffman said the collaboration “further validates the potential value of our…technology platform, especially in the areas of autoimmune disease, oncology and neuroscience.”

Elektrofi’s ultra-high concentration microparticle suspension technology platform aims to resolve the limitations associated with intravenously biologic therapies, with a focus on monoclonal antibodies, therapeutic proteins and other large molecule drugs.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构